Related Experiment Videos
A non-absorbable rifamycin for treatment of hepatic encephalopathy
Abstract:
Ammonia (NH3) plays a role in hepatic encephalopathy (HE). Agents affecting colonic ammonia production, such as non-absorbable antibiotics, decrease plasma levels of NH3 and findings of HE. The short-term efficacy of a non-absorbable rifamycin, rifaximin, was studied in comparison with paramomycin in 20 cirrhotic patients with high levels of NH3 and impaired number connection test (NCT). Both antibiotics significantly decreased ammonia-producing colonic bacteria. Rifaximin proved to be active on both aerobic and anaerobic bacteria and is thus effective, even at the dosage used, in the treatment of HE.
Insights
This study shows rifaximin effectively treats hepatic encephalopathy (HE) by reducing ammonia-producing gut bacteria. Rifaximin offers a promising therapeutic option for HE patients with high ammonia levels.
Area of Science:
- Hepatology
- Gastroenterology
- Microbiology
Background:
- Ammonia (NH3) significantly contributes to hepatic encephalopathy (HE) pathogenesis.
- Modulating colonic ammonia production, via non-absorbable antibiotics, can reduce NH3 levels and improve HE symptoms.
Purpose of the Study:
- To evaluate the short-term efficacy of rifaximin compared to paramomycin in cirrhotic patients with elevated NH3 and cognitive impairment (NCT).
Main Methods:
- A comparative study involving 20 cirrhotic patients with high NH3 and impaired NCT.
- Assessment of the impact of rifaximin and paramomycin on ammonia-producing colonic bacteria.
Main Results:
- Both rifaximin and paramomycin demonstrated a significant reduction in ammonia-producing colonic bacteria.
- Rifaximin exhibited activity against both aerobic and anaerobic bacteria.
Conclusions:
- Rifaximin is effective in treating hepatic encephalopathy, even at the tested dosage.
- The broad-spectrum activity of rifaximin contributes to its therapeutic benefits in HE.